Philippe Ledent, Chief Scientific Director at Xpress Biologics, now part of Sartorius, and Rakel Lopez de Maturana, Qualified Person & Regulatory Affairs Director at VIVEbiotech discussed how to ensure gain of time and success of lentiviral-based therapies from process development up to market approval.
The webinar can be watched here: https://globalmeet.webcasts.com/starthere.jsp?ei=1644258&tp_key=ac02d46070&sti=polyplus
If you prefer to read an interesting article as a summary, you can do so here: https://www.polyplus-sartorius.com/accelerating-lentiviral-vector-manufacturing-with-well-aligned-plasmid-and-vector-manufacturing-platforms